- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Patient Factors Influencing Antibiotic Selection in Uncomplicated UTIs
Panelists discuss how fluoroquinolones are generally reserved for uncomplicated urinary tract infections (UTIs) only when first-line options are contraindicated or pathogen resistance is confirmed, with treatment duration ranging from single-dose fosfomycin to 3 to 5 days for most antibiotics and 7 to 10 days for nitrofurantoin, noting shorter regimens typically achieve 85% to 95% adherence rates compared with 60% to 75% for longer courses, significantly affecting treatment success, particularly when patient factors such as adverse effects, dosing complexity, and lifestyle disruptions are considered.
EP: 1.Differentiating Uncomplicated and Complicated Urinary Tract Infections (UTIs)
EP: 2.Trends in Uncomplicated UTIs
EP: 3.Exploring Social Determinants of Health in Uncomplicated UTIs
EP: 4.Examining Uncomplicated UTI Recurrence
EP: 5.Role of Patients’ Education in Uncomplicated UTIs
EP: 6.Patient Burden Associated With Uncomplicated UTIs
EP: 7.Minimizing Antibiotic Resistance Development in Uncomplicated UTIs
EP: 8.Examining the Need for Updated Guidelines for Uncomplicated UTIs
EP: 9.Comparing Standard-of-Care Antibiotics for Uncomplicated UTIs
EP: 10.Patient Factors Influencing Antibiotic Selection in Uncomplicated UTIs
EP: 11.Recurrence Rates in Uncomplicated UTIs
EP: 12.Economic Burden Associated With Uncomplicated UTIs
EP: 13.Important Updates in the Management of Uncomplicated UTIs
EP: 14.Exploring Novel Options for the Management of Uncomplicated UTIs
EP: 15.Comparing Newer With Traditional Agents in Uncomplicated UTIs
EP: 16.Payer-Related Barriers With Therapies Used for Uncomplicated UTIs
EP: 17.Final Panel Thoughts on Uncomplicated UTI Management
Video content above is prompted by the following:
- In which clinical scenarios would the use of other therapies, such as fluoroquinolones, be recommended for treating uncomplicated UTIs, and what factors guide the decision to choose these over preferred treatments?
- How does the duration of therapy differ across treatment options, and how does this affect patient adherence rates and treatment success?
Real-World Data Show Bevacizumab Benefits Only High-Risk Patients With Epithelial Ovarian Cancer
May 13th 2025In line with previous clinical trial findings, real-world data show that bevacizumab improves outcomes in patients with epithelial ovarian cancer and high-risk prognostic factors.
Read More
Global Analysis Sheds Light on Women’s Cancer Trends
May 11th 2025As National Women’s Health Week approaches, new global data highlighting projected rises in breast and ovarian cancer through 2050 is prompting renewed calls for gender-specific prevention strategies that address evolving health risks for women.
Read More
